

cnt
A, ex 11103

now U.S. Pat No. 6,277,819 B1
filed August 21, 1997.

In the Claims

Please cancel all claims and add the following new claims.

- 13.22. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a pharmaceutical composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, a buffer, and a preservative at a dose effective to normalize blood glucose.
- 14.23. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, wherein the administration occurs within the first 72 hours following a myocardial infarction.
- 15.24. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a GLP-1 derivative at a dose effective to normalize blood glucose.
- 16.25. The method of Claim 24, wherein the GLP-1 derivative is a GLP-1 analog having an acylated lysine ϵ -amino group.
- 17.26. The method of Claim 22, wherein the compound is complexed with a divalent metal cation.
- 18.27. The method of Claim 22, wherein the preservative is selected from the group consisting of meta-cresol and phenol.